دورية أكاديمية
Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis.
| العنوان: | Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. |
|---|---|
| المؤلفون: | Younossi, Zobair M, Stepanova, Maria, Anstee, Quentin M, Lawitz, Eric J, Wai-Sun Wong, Vincent, Romero-Gomez, Manuel, Kersey, Kathryn, Li, Georgia, Subramanian, G Mani, Myers, Robert P, Djedjos, C Stephen, Okanoue, Takeshi, Trauner, Michael, Goodman, Zachary, Harrison, Stephen A |
| سنة النشر: | 2019 |
| المجموعة: | Sistema Sanitario Público de Andalucía (SSPA): Repositorio |
| مصطلحات موضوعية: | BMI, Emotional, NAFLD, Physical Function, Utilities, Body Mass Index, Comorbidity, Diabetes Mellitus, Type 2, Female, Humans, Liver Cirrhosis, Male, Middle Aged, Non-alcoholic Fatty Liver Disease, Patient Reported Outcome Measures, Severity of Illness Index, Sex Factors, Smoking, Surveys and Questionnaires |
| الوصف: | Patient-reported outcomes (PROs) are used to measure patients' experience with their disease. However, there are few PRO data from patients with NASH. We collected data from the STELLAR clinical trials to assess PROs for NASH and advanced fibrosis. We analyzed data from 1667 patients (58 ± 9 years, 40% male, 52% with cirrhosis, 74% with diabetes) with NASH and bridging fibrosis or compensated cirrhosis (metavir scores, F3 or F4) enrolled in the phase 3 STELLAR trials of selonsertib (NCT03053050 and NCT03053063) who completed PRO questionnaires (SF-36, CLDQ-NASH, EQ-5D, or WPAI:SHP) before treatment initiation. Compared with patients with F3 fibrosis, higher proportions of patients with F4 fibrosis were female, were white, had more hematologic and gastrointestinal comorbidities, and had type 2 diabetes (P ≤ .01). Mean physical health-related PRO scores were significantly lower than those of the general population: patients with F4 fibrosis had score reductions of 4.4% to 12.9% in 6/8 SF-36 domains and patients with F3 fibrosis had score reductions of 3.9% to 11.7% in 4/8 domains (P PROs are significantly lower in patients with NASH with advanced fibrosis who participated in the STELLAR clinical trials. Treatment of patients with NASH should focus on improving not only clinical outcomes but also quantifiable symptom burden and health-related quality of life. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1542-7714 |
| العلاقة: | http://hdl.handle.net/10668/13588Test; http://www.cghjournal.org/article/S1542356519301879/pdfTest |
| DOI: | 10.1016/j.cgh.2019.02.024 |
| الإتاحة: | https://doi.org/10.1016/j.cgh.2019.02.024Test http://hdl.handle.net/10668/13588Test http://www.cghjournal.org/article/S1542356519301879/pdfTest |
| حقوق: | open access |
| رقم الانضمام: | edsbas.1E13B10D |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 15427714 |
|---|---|
| DOI: | 10.1016/j.cgh.2019.02.024 |